Aclaris Therapeutics
ACRS
81 hedge funds and large institutions have $58.5M invested in Aclaris Therapeutics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 29 reducing their positions, and 25 closing their positions.
1,017% more call options, than puts
Call options by funds: $67K | Put options by funds: $6K
1% more capital invested
Capital invested by funds: $58.1M → $58.5M (+$396K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.83% less ownership
Funds ownership: 74.17% → 71.35% (-2.8%)
17% less funds holding
Funds holding: 98 → 81 (-17)
28% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 29
68% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.55M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.12M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$652K |
| 4 |
Renaissance Technologies
New York
|
+$550K |
| 5 |
Morgan Stanley
New York
|
+$361K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.1M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$795K |
| 3 |
Goldman Sachs
New York
|
-$754K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$626K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$482K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$3.85K | -3,497 | Closed |
|
102
New York State Common Retirement Fund
Albany,
New York
| – | -$645 | -586 | Closed |
|
103
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$327 | -267 | -100% |
|
|
IC
104
Innealta Capital
Austin,
Texas
| – | -$62 | -56 | Closed |
|
ACRS Hedge Fund Activity: Q3 2024 in Review
81 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2024, worth a combined $58.5M — up 0.68% from $58.1M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ACRS and 8 opened new positions — a net loss of 17 holders — while 29 trimmed existing stakes and 21 added.
The largest buyer was BML Capital Management, adding an estimated $1.55M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $1.1M sold.
- 81 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2024, down from 98 in Q2 2024.
- Funds reported $58.5M of Aclaris Therapeutics stock for Q3 2024, up 0.68% quarter-over-quarter.
- 8 funds opened new Aclaris Therapeutics positions in Q3 2024 and 25 closed out, a net change of -17 holders.
- The largest Aclaris Therapeutics buyer in Q3 2024 was BML Capital Management, an estimated $1.55M added.
- The largest Aclaris Therapeutics seller in Q3 2024 was Bain Capital Life Sciences Investors, an estimated $1.1M sold.
Based on aggregated 13F filings for Q3 2024.